Form 8-K - Current report:
SEC Accession No. 0001193125-26-308342
Filing Date
2026-07-20
Accepted
2026-07-20 07:34:30
Documents
18
Period of Report
2026-07-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d40931d8k.htm   iXBRL 8-K 33317
2 EX-1.1 d40931dex11.htm EX-1.1 156603
3 EX-4.1 d40931dex41.htm EX-4.1 68408
4 EX-5.1 d40931dex51.htm EX-5.1 16943
5 EX-99.1 d40931dex991.htm EX-99.1 12131
9 GRAPHIC g40931g0719233228320.jpg GRAPHIC 1878
10 GRAPHIC g40931g0719233228635.jpg GRAPHIC 8297
11 GRAPHIC g40931g0719233228790.jpg GRAPHIC 6209
  Complete submission text file 0001193125-26-308342.txt   495424

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA rgnx-20260716.xsd EX-101.SCH 3171
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgnx-20260716_lab.xml EX-101.LAB 17233
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgnx-20260716_pre.xml EX-101.PRE 10806
21 EXTRACTED XBRL INSTANCE DOCUMENT d40931d8k_htm.xml XML 3498
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37553 | Film No.: 261185172
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)